Editas targets EDIT-401 CTN submission
- Editas Medicine said on August 5 that EDIT-401 remains on track for an Australian Clinical Trial Notification filing this month. - The company said a single EDIT-401 dose cut LDL-C, Lp(a) and ApoB by about 90% or more in non-human primates. - Editas said it expects an EDIT-401 data update in the first quarter of 2027.
Editas Medicine said on August 5 that it remains on track to submit a Clinical Trial Notification, or CTN, in Australia this month for EDIT-401, its in vivo CRISPR candidate for hyperlipidemia. The update came with the company’s second-quarter 2026 results and a fresh timeline for a data update in the first quarter of 2027. Gilmore O’Neill, Editas’s president and chief executive, said the company “continued preclinical work” during the second quarter to support moving EDIT-401 into a single-ascending-dose, open-label Phase 1/2 study. The company said the planned trial is aimed at patients with heterozygous familial hypercholesterolemia, or HeFH. (ir.editasmedicine.com) ### What is Editas actually filing this month? Australia’s CTN pathway is the regulatory step Editas said it plans to use to start first-in-human testing of EDIT-401. In its August 5 release, the company said it is on track to submit that CTN this month and continues to progress toward initiating a Phase 1/2 clinical trial in HeFH patients. (ir.editasmedicine.com) May 26 was the last time Editas publicly laid out this timing in detail, saying then that it expected to submit a CTN in Australia by mid-2026 and seek early in vivo human proof-of-concept data by the end of 2026. The August update keeps the filing on the near-term calendar but shifts the next named data marker to the first quarter of 2027. (ir.editasmedicine.com) ### What is EDIT-401 designed to do? EDIT-401 is Editas’s lead in vivo development candidate and targets LDLR, the low-density lipoprotein receptor pathway. The company has described it as an LDL cholesterol-lowering medicine for hyperlipidemia and has said the first clinical study is planned for patients with HeFH, a genetic disorder linked to elevated LDL cholesterol. (ir.editasmedicine.com) May conference materials and the August results release describe the program as a one-time treatment approach intended to lower multiple atherogenic lipoproteins. O’Neill said the latest preclinical package reinforced EDIT-401’s potential as a “best-in-class, one-time treatment for hyperlipidemia,” though that characterization is the company’s own description and the drug remains preclinical. (ir.editasmedicine.com) ### What data did Editas highlight? Editas said on August 5 that a single dose of EDIT-401 achieved about 90% or greater mean reductions in LDL cholesterol, lipoprotein(a), and apolipoprotein B in non-human primates, with rapid and dose-dependent effects. The company also said LDL-C mean reduction of at least 90% was durable through about six months in those animals. (ir.editasmedicine.com) The company added that no adverse clinical observations were seen in non-human primates at a single dose of 1.5 mg/kg. Those data were previously presented at the European Atherosclerosis Society Congress, the American Society of Gene and Cell Therapy annual meeting, and the TIDES USA 2026 conference, according to Editas. (ir.editasmedicine.com) ### How does the financing fit into this update? Editas said cash and cash equivalents totaled $211.6 million as of June 30, up from $146.6 million at the end of 2025. The company said that cash position is expected to fund operating expenses and capital spending into the second half of 2028. (ir.editasmedicine.com) May 26 was also the date of Editas’s public offering announcement, which priced 55.6 million shares and accompanying warrants at a combined public offering price of $2.25 per share-and-warrant package, for gross proceeds of about $125 million before expenses. In the August release, Editas linked that financing directly to continued development of EDIT-401. (ir.editasmedicine.com) ### What should readers watch next? August 2026 is the next concrete milestone because Editas said the Australian CTN submission is expected this month. After that, the company’s next stated checkpoint is an EDIT-401 data update in the first quarter of 2027, tied to the planned Phase 1/2 study in HeFH patients. (ir.editasmedicine.com 1) (ir.editasmedicine.com 2)